Half Moon Medical’s Pilot Study of TMVR System Continues Enrollment

May 31, 2024—Half Moon Medical announced the treatment of 15 patients with the second-generation Half Moon transcatheter mitral valve repair (TMVR) device. The procedures were part of the company’s pilot study of the technology being conducted in the United and Australia.

Additionally, the company announced that the Half Moon device will be featured in two presentations at the New York Valves conference held June 5-7 in New York, New York.

According to the company, the investigational Half Moon TMVR device is designed to restore mitral valve function in patients with severe symptomatic mitral regurgitation (MR). Half Moon stated that the device has been shown to produce significant, sustained reduction in MR without an increase in pressure gradient across the valve in a wide range of valve anatomies not addressable by other percutaneous therapies.

Stan Chetcuti, MD, who treated the 15th patient in the newly announced cohort, is the Director of the Cardiac Catheterization Laboratory at the University of Michigan in Ann Arbor, Michigan.

“The Half Moon device allowed us to successfully treat a patient with severe MR who had no other meaningful treatment options,” commented Dr. Chetcuti in the company’s press release. “We are very excited about the opportunity to expand our percutaneous toolbox for the treatment of mitral valve disease.”

On June 5 at the New York Valves conference. Azeem Latib, MD, will present interim data from the Half Moon pilot study. On June 6, Hemal Gada, MD, will present a case he performed with the Half Moon device in a patient with complex mitral valve pathology that could not be addressed by transcatheter edge-to-edge mitral valve repair or transcatheter mitral valve replacement.

Dr. Latib is System Director of Interventional Cardiology at Montefiore Health System in New York, New York. Dr. Gada is President of UPMC Heart and Vascular Institute in Harrisburg, Pennsylvania.